|
Archived Monthly Oncology Tumor Boards: Sequencing Therapies for Patients with Metastatic HER2-Negative Breast Cancer |
1.00 |
03/06/2024 - 12:00am to 03/06/2025 - 12:00am |
|
NCCN Guidelines® Insights - Mesothelioma: Pleural, Version 1.2024 |
1.00 |
03/10/2024 - 12:00am to 03/10/2025 - 12:00am |
|
Multigene and Biomarker Testing in Breast Cancer |
1.00 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
|
Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates |
1.25 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
|
Locoregional Management of Breast Cancer with SABCS Updates |
1.25 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
|
Advances in the Management of Metastatic Breast Cancer with SABCS Updates |
1.00 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
|
Issues with Sexuality and Sexual Function in Patients with Breast Cancer |
1.00 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
|
Cardiovascular Health After Breast Cancer Treatment |
0.50 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
|
Monthly Oncology Tumor Boards: Updates in Treatment of Hairy Cell Leukemia |
1.00 |
03/19/2024 - 12:00am to 08/04/2024 - 12:00am |
|
Monthly Oncology Tumor Boards: B-Cell Lymphomas: Histologic Transformation of Indolent Lymphomas |
1.00 |
03/19/2024 - 12:00am to 08/04/2024 - 12:00am |
|
Recorded Presentation from the NCCN Pharmacy Updates: The Growing Impact of Pharmacogenomics Across the Oncology Landscape |
1.00 |
03/21/2024 - 12:00am to 03/21/2025 - 12:00am |
|
NCCN Guidelines® Insights - Prostate Cancer, Version 3.2024 |
1.00 |
04/10/2024 - 12:00am to 04/10/2025 - 12:00am |
Facebook
Twitter
LinkedIn
Forward